AU2005209256B2 - Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis - Google Patents

Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis Download PDF

Info

Publication number
AU2005209256B2
AU2005209256B2 AU2005209256A AU2005209256A AU2005209256B2 AU 2005209256 B2 AU2005209256 B2 AU 2005209256B2 AU 2005209256 A AU2005209256 A AU 2005209256A AU 2005209256 A AU2005209256 A AU 2005209256A AU 2005209256 B2 AU2005209256 B2 AU 2005209256B2
Authority
AU
Australia
Prior art keywords
mmtv
tenofovir
adefovir
breast cancer
pbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005209256A
Other languages
English (en)
Other versions
AU2005209256A1 (en
Inventor
Tomas Cihlar
Janet L. Douglas
Craig S. Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2005209256A1 publication Critical patent/AU2005209256A1/en
Application granted granted Critical
Publication of AU2005209256B2 publication Critical patent/AU2005209256B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2005209256A 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis Ceased AU2005209256B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
US60/538,066 2004-01-21
PCT/US2005/002043 WO2005072748A1 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis

Publications (2)

Publication Number Publication Date
AU2005209256A1 AU2005209256A1 (en) 2005-08-11
AU2005209256B2 true AU2005209256B2 (en) 2010-11-18

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005209256A Ceased AU2005209256B2 (en) 2004-01-21 2005-01-21 Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis

Country Status (10)

Country Link
US (2) US20070281911A1 (cg-RX-API-DMAC7.html)
EP (1) EP1732569B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007518815A (cg-RX-API-DMAC7.html)
AT (1) ATE445404T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005209256B2 (cg-RX-API-DMAC7.html)
CA (1) CA2553455A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017131D1 (cg-RX-API-DMAC7.html)
ES (1) ES2334149T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ548532A (cg-RX-API-DMAC7.html)
WO (1) WO2005072748A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
ATE534377T1 (de) 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
ES2566762T3 (es) * 2009-10-05 2016-04-15 Ambergen Inc. Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
WO2020171225A1 (ja) * 2019-02-22 2020-08-27 一素 村田 mTOR阻害剤
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
EP3993873A4 (en) * 2019-07-02 2023-09-20 Virago Vax Inc. SUPPRESSION OF BREAST TUMORS
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000829A2 (en) * 1999-06-30 2001-01-04 Tulane University Medical Center Human endogenous retrovirus in breast cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073507A2 (en) * 1999-06-01 2000-12-07 Alton Ochsner Medical Foundation Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
HRP20030047B1 (hr) * 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000829A2 (en) * 1999-06-30 2001-01-04 Tulane University Medical Center Human endogenous retrovirus in breast cancer

Also Published As

Publication number Publication date
ATE445404T1 (de) 2009-10-15
CA2553455A1 (en) 2005-08-11
EP1732569B1 (en) 2009-10-14
US20050239753A1 (en) 2005-10-27
HK1099228A1 (en) 2007-08-10
AU2005209256A1 (en) 2005-08-11
EP1732569A1 (en) 2006-12-20
JP2007518815A (ja) 2007-07-12
ES2334149T3 (es) 2010-03-05
WO2005072748A1 (en) 2005-08-11
US20070281911A1 (en) 2007-12-06
DE602005017131D1 (de) 2009-11-26
NZ548532A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
EP1732569B1 (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
Lin et al. Inhibitory effects of some derivatives of glycyrrhizic acid against Epstein-Barr virus infection: Structure–activity relationships
HUE026849T2 (en) Therapeutic combination containing dolutegravir, abacavir and lamivudine
JP2001500471A (ja) プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
CA2853495A1 (en) Methods and compositions for treating hepatitis c virus
US20250099476A1 (en) Solid forms of a nucleoside analogue and uses thereof
JP2020203947A (ja) Ns5a、ns5bまたはns3阻害剤を使用する、b型肝炎ウイルス感染症を処置するための方法
WO2013012477A1 (en) Propolis and caffeic acid phenethyl ester and uses thereof
US20230158103A1 (en) Pld for use in combination in the treatment of coronavirus
MX2010010082A (es) Utilización de 4'-thio-2'-deoxinucleótidos como agentes anti-orthopoxvirus.
WO2015120057A1 (en) Pharmaceutical combinations against co-infection with hiv and tuberculosis
CN111587107B (zh) 药物组合物
HK1099228B (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
US7615542B2 (en) Dioxolane thymine and combinations for use against 3TC/AZT resistant strains of HIV
CA2501717C (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
CN1302779C (zh) 含有阿巴卡韦和阿洛夫定的药物制剂及其用途
CN114903891B (zh) 沙奎那韦在治疗或预防乙型肝炎中的应用
US12616692B2 (en) Method of achieving HIV viral remission using long-acting antiretroviral agents
CN114099517B (zh) 苯并咪唑类化合物在治疗或预防乙型肝炎中的应用
AU2017268621A1 (en) Antiviral therapy
Foggia et al. Tenofovir disoproxil fumarate in the clinical practice: An overview
CN115518072A (zh) 一种用于治疗病毒性肝炎的药物组合物
CN110623968A (zh) 伊文思蓝在制备药物中的用途及药物组合物
US20090291908A1 (en) Use of thiophoshonoformic acid and nrtis to treat viral infections
Khoury et al. ODE-adefovir exhibits potent in vitro and in vivo cytotoxic activity and has synergistic effect with ara-c in AML

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired